Abstract
Langerhans cell histiocytosis (LCH) is an enigmatic disease usually occurring in children. Tumor lysis syndrome (TLS) is a clinical syndrome associated with severe metabolic derangement and oliguric acute renal failure. In this report, we present the clinical course of an infant with advanced LCH who had TLS develop after chemotherapy. Treatment with continuous arteriovenous hemofiltration resulted in effective control of serum uric acid, potassium, creatinine, phosphorus, and blood urea nitrogen levels in the blood.
MeSH terms
-
Acute Kidney Injury / etiology
-
Allopurinol / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Biomarkers
-
Blood Transfusion
-
Combined Modality Therapy
-
Disease Progression
-
Etoposide / administration & dosage
-
Fatal Outcome
-
Female
-
Fluid Therapy
-
Hemofiltration*
-
Histiocytosis, Langerhans-Cell / complications*
-
Histiocytosis, Langerhans-Cell / drug therapy
-
Humans
-
Infant
-
L-Lactate Dehydrogenase / blood
-
Lymph Nodes / pathology
-
Mercaptopurine / administration & dosage
-
Multiple Organ Failure / etiology
-
Neck
-
Orbital Diseases / complications*
-
Orbital Diseases / drug therapy
-
Prednisolone / administration & dosage
-
Sodium Bicarbonate / therapeutic use
-
Temporal Bone / pathology*
-
Tumor Lysis Syndrome / blood
-
Tumor Lysis Syndrome / etiology
-
Tumor Lysis Syndrome / therapy*
-
Uric Acid / blood
-
Vinblastine / administration & dosage
-
Vincristine / administration & dosage
Substances
-
Biomarkers
-
Uric Acid
-
Vincristine
-
Vinblastine
-
Allopurinol
-
Etoposide
-
Sodium Bicarbonate
-
Prednisolone
-
Mercaptopurine
-
L-Lactate Dehydrogenase